Logo image of VBLT

VASCULAR BIOGENICS LTD (VBLT) Stock Fundamental Analysis

NASDAQ:VBLT - IL0011327454 - Common Stock

0.156 USD
-0.02 (-8.77%)
Last: 10/16/2023, 8:02:23 PM
0.168 USD
+0.01 (+7.69%)
After Hours: 10/16/2023, 8:02:23 PM
Fundamental Rating

3

Overall VBLT gets a fundamental rating of 3 out of 10. We evaluated VBLT against 547 industry peers in the Biotechnology industry. While VBLT seems to be doing ok healthwise, there are quite some concerns on its profitability. VBLT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

VBLT had negative earnings in the past year.
In the past year VBLT has reported a negative cash flow from operations.
In the past 5 years VBLT always reported negative net income.
VBLT had a negative operating cash flow in each of the past 5 years.
VBLT Yearly Net Income VS EBIT VS OCF VS FCFVBLT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -10M -20M -30M

1.2 Ratios

With a Return On Assets value of -64.74%, VBLT is not doing good in the industry: 64.62% of the companies in the same industry are doing better.
VBLT has a Return On Equity of -82.94%. This is comparable to the rest of the industry: VBLT outperforms 46.35% of its industry peers.
Industry RankSector Rank
ROA -64.74%
ROE -82.94%
ROIC N/A
ROA(3y)-71.09%
ROA(5y)-57.33%
ROE(3y)-93.2%
ROE(5y)-74.41%
ROIC(3y)N/A
ROIC(5y)N/A
VBLT Yearly ROA, ROE, ROICVBLT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 -50 -100

1.3 Margins

VBLT has a better Gross Margin (96.47%) than 97.01% of its industry peers.
In the last couple of years the Gross Margin of VBLT has declined.
The Profit Margin and Operating Margin are not available for VBLT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 96.47%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y11.51%
GM growth 5Y-2.9%
VBLT Yearly Profit, Operating, Gross MarginsVBLT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -1K -2K -3K -4K

More info and screens

6

2. Health

2.1 Basic Checks

VBLT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VBLT has been increased compared to 1 year ago.
VBLT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
VBLT Yearly Shares OutstandingVBLT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M
VBLT Yearly Total Debt VS Total AssetsVBLT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M

2.2 Solvency

VBLT has an Altman-Z score of -16.80. This is a bad value and indicates that VBLT is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -16.80, VBLT is doing worse than 87.54% of the companies in the same industry.
There is no outstanding debt for VBLT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -16.8
ROIC/WACCN/A
WACC8.55%
VBLT Yearly LT Debt VS Equity VS FCFVBLT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 4.63 indicates that VBLT has no problem at all paying its short term obligations.
The Current ratio of VBLT (4.63) is comparable to the rest of the industry.
A Quick Ratio of 4.63 indicates that VBLT has no problem at all paying its short term obligations.
With a Quick ratio value of 4.63, VBLT perfoms like the industry average, outperforming 45.51% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.63
Quick Ratio 4.63
VBLT Yearly Current Assets VS Current LiabilitesVBLT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 56.41% over the past year.
The Revenue for VBLT has decreased by -15.91% in the past year. This is quite bad
VBLT shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -45.64% yearly.
EPS 1Y (TTM)56.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.85%
Revenue 1Y (TTM)-15.91%
Revenue growth 3Y5.52%
Revenue growth 5Y-45.64%
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, VBLT will show a very negative growth in Earnings Per Share. The EPS will decrease by -11.84% on average per year.
Based on estimates for the next years, VBLT will show a very strong growth in Revenue. The Revenue will grow by 29.94% on average per year.
EPS Next Y-15.38%
EPS Next 2Y-19.29%
EPS Next 3Y-15.92%
EPS Next 5Y-11.84%
Revenue Next Year68.85%
Revenue Next 2Y29.94%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VBLT Yearly Revenue VS EstimatesVBLT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
VBLT Yearly EPS VS EstimatesVBLT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -5 -10 -15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VBLT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VBLT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VBLT Price Earnings VS Forward Price EarningsVBLT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VBLT Per share dataVBLT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6

4.3 Compensation for Growth

VBLT's earnings are expected to decrease with -15.92% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-19.29%
EPS Next 3Y-15.92%

More info and screens

0

5. Dividend

5.1 Amount

VBLT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VASCULAR BIOGENICS LTD

NASDAQ:VBLT (10/16/2023, 8:02:23 PM)

After market: 0.168 +0.01 (+7.69%)

0.156

-0.02 (-8.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2023-08-14/bmo
Earnings (Next)11-13 2023-11-13/bmo
Inst Owners0%
Inst Owner Change0%
Ins Owners8.48%
Ins Owner Change0%
Market Cap12.11M
Analysts45.71
Price Target5.1 (3169.23%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 25.18
P/FCF N/A
P/OCF N/A
P/B 0.63
P/tB 0.63
EV/EBITDA N/A
EPS(TTM)-0.21
EYN/A
EPS(NY)-0.75
Fwd EYN/A
FCF(TTM)-0.23
FCFYN/A
OCF(TTM)-0.23
OCFYN/A
SpS0.01
BVpS0.25
TBVpS0.25
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -64.74%
ROE -82.94%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 96.47%
FCFM N/A
ROA(3y)-71.09%
ROA(5y)-57.33%
ROE(3y)-93.2%
ROE(5y)-74.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y11.51%
GM growth 5Y-2.9%
F-Score5
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 8.68%
Cap/Sales 6.44%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.63
Quick Ratio 4.63
Altman-Z -16.8
F-Score5
WACC8.55%
ROIC/WACCN/A
Cap/Depr(3y)65.86%
Cap/Depr(5y)79.11%
Cap/Sales(3y)106.53%
Cap/Sales(5y)142.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)56.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.85%
EPS Next Y-15.38%
EPS Next 2Y-19.29%
EPS Next 3Y-15.92%
EPS Next 5Y-11.84%
Revenue 1Y (TTM)-15.91%
Revenue growth 3Y5.52%
Revenue growth 5Y-45.64%
Sales Q2Q%-100%
Revenue Next Year68.85%
Revenue Next 2Y29.94%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y54.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y22.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y21.09%
OCF growth 3YN/A
OCF growth 5YN/A